title: Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa.
abstract: Pseudomonas aeruginosa is the most common pathogen infecting the lower respiratory tract of cystic fibrosis (CF) patients, where it forms tracheobronchial biofilms. Pseudomonas biofilms are refractory to antibacterials and to phagocytic cells with innate immunity, leading to refractory infection. Little is known about the interaction between antipseudomonal agents and phagocytic cells in eradication of P. aeruginosa biofilms. Herein, we investigated the capacity of three antipseudomonal agents, amikacin (AMK), ceftazidime (CAZ), and ciprofloxacin (CIP), to interact with human polymorphonuclear leukocytes (PMNs) against biofilms and planktonic cells of P. aeruginosa isolates recovered from sputa of CF patients. Three of the isolates were resistant and three were susceptible to each of these antibiotics. The concentrations studied (2, 8, and 32 mg/liter) were subinhibitory for biofilms of resistant isolates, whereas for biofilms of susceptible isolates, they ranged between sub-MIC and 2 × MIC values. The activity of each antibiotic alone or in combination with human PMNs against 48-h mature biofilms or planktonic cells was determined by XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] assay. All combinations of AMK with PMNs resulted in synergistic or additive effects against planktonic cells and biofilms of P. aeruginosa isolates compared to each component alone. More than 75% of CAZ combinations exhibited additive interactions against biofilms of P. aeruginosa isolates, whereas CIP had mostly antagonistic interaction or no interaction with PMNs against biofilms of P. aeruginosa. Our findings demonstrate a greater positive interaction between AMK with PMNs than that observed for CAZ and especially CIP against isolates of P. aeruginosa from the respiratory tract of CF patients.
authors: Infectious Diseases Laboratory, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece.
authors: Athanasios
authors: A
authors: Chatzimoschou
authors: Infectious Diseases Laboratory, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece.
authors: Maria
authors: M
authors: Simitsopoulou
authors: Infectious Diseases Laboratory, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece.
authors: Charalampos
authors: C
authors: Antachopoulos
authors: Transplantation-Oncology Infectious Diseases Program, Departments of Medicine, Pediatrics, and Microbiology & Immunology, Weill Cornell Medical Center of Cornell University, New York, New York, USA.
authors: Thomas J
authors: TJ
authors: Walsh
authors: Infectious Diseases Laboratory, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece roilides@med.auth.gr.
authors: Emmanuel
authors: E
authors: Roilides
mesh_terms: D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D002442:Ceftazidime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D009504:Neutrophils / Q000187:drug effects*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013183:Sputum / Q000166:cytology
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D000583:Amikacin; D002442:Ceftazidime
references: Diagn Microbiol Infect Dis. 1993 May-Jun;16(4):277-89
references: 8388327
references: Int J Antimicrob Agents. 2006 Mar;27(3):196-200
references: 16459057
references: Drug Dev Ind Pharm. 2008 Oct;34(10):1090-6
references: 18777242
references: Br Med Bull. 2009;89:93-110
references: 19155262
references: Can J Microbiol. 1988 Jan;34(1):12-8
references: 3132316
references: Front Microbiol. 2011 Apr 05;2:65
references: 21747788
references: FEMS Immunol Med Microbiol. 2010 Aug;59(3):292-305
references: 20579098
references: Thorax. 2010 Jan;65(1):57-62
references: 19846469
references: Crit Care. 2009;13(6):R200
references: 20003269
references: Infect Immun. 1993 Apr;61(4):1185-93
references: 7681040
references: Int Wound J. 2006 Sep;3(3):225-31
references: 16984578
references: Antimicrob Agents Chemother. 1991 Dec;35(12):2521-5
references: 1810184
references: Lett Appl Microbiol. 2010 Sep;51(3):331-7
references: 20681967
references: Antimicrob Agents Chemother. 2008 Oct;52(10):3648-63
references: 18644954
references: J Antimicrob Chemother. 1990 Nov;26 Suppl C:49-57
references: 2127416
references: J Med Microbiol. 2004 Sep;53(Pt 9):903-10
references: 15314198
references: Chemotherapy. 1991;37(2):114-21
references: 1903340
references: Microbiology. 2007 May;153(Pt 5):1329-38
references: 17464047
references: Antimicrob Agents Chemother. 1974 May;5(5):508-12
references: 4462465
references: Chemotherapy. 1997 Sep-Oct;43(5):340-5
references: 9309367
references: PLoS Pathog. 2008 Nov;4(11):e1000213
references: 19023416
references: Pathog Dis. 2014 Apr;70(3):440-3
references: 24376174
references: Chest. 2004 Feb;125(2 Suppl):62S-69S; quiz 69S
references: 14872002
references: J Microbiol Methods. 2008 Feb;72(2):157-65
references: 18155789
references: Front Microbiol. 2014 Jan 08;4:422
references: 24409175
references: Infect Immun. 2012 Aug;80(8):2601-7
references: 22585963
references: Antimicrob Agents Chemother. 2003 Jan;47(1):317-23
references: 12499208
references: Chemotherapy. 1999 Jul-Aug;45(4):268-76
references: 10394010
references: Respirology. 2010 Oct;15(7):1037-56
references: 20723140
references: Microbiology. 2009 Nov;155(Pt 11):3500-8
references: 19643762
references: J Antimicrob Chemother. 1990 Jun;25(6):941-8
references: 2115038
references: J Antimicrob Chemother. 2001 Aug;48(2):325-7
references: 11481316
references: Curr Mol Pharmacol. 2008 Jan;1(1):68-79
references: 20021425
references: Microbiology. 2005 Feb;151(Pt 2):373-83
references: 15699188
references: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17025-30
references: 12482953
references: J Bacteriol. 2007 May;189(9):3603-12
references: 17337585
references: J Antimicrob Chemother. 1997 Nov;40(5):615-21
references: 9421308
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3281-8
references: 16048937
references: J Immunol. 2003 Oct 15;171(8):4329-39
references: 14530358
references: J Clin Pharmacol. 1986 Mar;26(3):222-6
references: 2937812
references: Infect Immun. 1990 Jul;58(7):2383-5
references: 2114367
references: J Antimicrob Chemother. 2005 Nov;56(5):879-86
references: 16188918
references: Clin Microbiol Rev. 2002 Apr;15(2):194-222
references: 11932230
references: Pathology. 2004 Dec;36(6):571-5
references: 15841693
references: Drugs. 2007;67(3):351-68
references: 17335295
references: Expert Rev Anti Infect Ther. 2012 Mar;10(3):319-40
references: 22397566
references: Int J Antimicrob Agents. 2011 Apr;37(4):309-15
references: 21382698
references: Antimicrob Agents Chemother. 2013 Jun;57(6):2694-704
references: 23545534
references: Methods Find Exp Clin Pharmacol. 1998 Dec;20(10):819-24
references: 10091217
references: Antimicrob Agents Chemother. 2011 May;55(5):1968-74
references: 21343465